Antimicrobial-resistant Shigella: where do we go next?

[1]  F. Weill,et al.  The evolution and international spread of extensively drug resistant Shigella sonnei , 2023, Nature Communications.

[2]  C. MacLennan,et al.  The Shigella Vaccines Pipeline , 2022, Vaccines.

[3]  P. Pavlinac,et al.  The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella spp , 2022, eLife.

[4]  Christine J. Boinett,et al.  Commensal E. coli are a reservoir for the transfer of XDR plasmids into epidemic fluoroquinolone-resistant Shigella sonnei , 2019, Nature Microbiology.

[5]  P. Sansonetti,et al.  Shigella Pathogenesis: New Insights through Advanced Methodologies , 2019, Microbiology spectrum.

[6]  C. Murray,et al.  Morbidity and mortality due to shigella and enterotoxigenic Escherichia coli diarrhoea: the Global Burden of Disease Study 1990–2016 , 2018, The Lancet. Infectious diseases.

[7]  Stephen S. Lim,et al.  The changing patterns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Disease Study 1990–2016 , 2018, The Lancet. Global health.

[8]  Julian Parkhill,et al.  Tracking the establishment of local endemic populations of an emergent enteric pathogen , 2013, Proceedings of the National Academy of Sciences.

[9]  D. W. Kim,et al.  Shigella sonnei genome sequencing and phylogenetic analysis indicate recent global dissemination from Europe , 2012, Nature Genetics.

[10]  T. L. Hale,et al.  Shigella vaccines. , 1989, Reviews of infectious diseases.